Inclusion Criteria:

- Age ≥ 18 years.

- Patient with multiple myeloma who received 1 to 3 lines of treatment (including
high-dose chemotherapy with stem cell support, conventional poli-chemotherapy,
thalidomide- , bortezomib- and melphalan-based regimens) and is relapsed or relapsed
and refractory (that means relapsed while on salvage or progression within 60 days of
most recent therapy) to lenalidomide therapy.

- Patient has clinical relapse of MM based on standard criteria.

- Patient has measurable disease, defined as follows:

- For secretory multiple myeloma, measurable disease is defined as any
quantifiable serum monoclonal protein value (greater than 1 g/dL of IgG
M-protein, greater than 0.5 g/dL of IgA M-protein or IgD M-protein OR urine
light-chain excretion of more than 200 mg/24 hours)

- For oligo- or non-secretory multiple myeloma, measurable disease is defined by
the presence of measurable soft tissue (not bone) plasmacytomas as determined by
clinical examination or applicable radiographs (i.e., MRI, CT scan).

A measurable lesion is defined as a lesion with minimum largest diameter of >20 mm (if
measured by conventional techniques such as physical exam, conventional CT scan, MRI) or
of >10 mm (if measured by spiral CT scan) in one dimension.

- Patient has a Karnofsky performance status ≥ 60%.

Exclusion Criteria:

- Any serious medical condition, laboratory abnormality, or psychiatric illness that
would prevent the subject from signing the informed consent form.

- Pregnant or breast feeding females.

- Any condition, including the presence of laboratory abnormalities, which places the
subject at unacceptable risk if he/she were to participate in the study or confounds
the ability to interpret data from the study.

- Use of any other concomitant standard/experimental anti-myeloma drug or therapy.

- Uncontrolled or severe cardiovascular disease including myocardial infarction within
6 months of enrolment, New York Heart Association (NYHA) Class III or IV heart
failure, uncontrolled angina, clinically significant pericardial disease, or cardiac
amyloidosis Other malignancy within the past 5 years. Exceptions: basal cell or non
metastatic squamous cell carcinoma of the skin, cervical carcinoma in situ or FIGO
Stage 1 carcinoma of the cervix.

- Concurrent medical condition or disease (e.g., active systemic infection,
uncontrolled diabetes, pulmonary disease, cardiac disease) that is likely to
interfere with study procedures or results, or that in the opinion of the
investigator would constitute a hazard for participating in this study.